Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Equity Average (2016 - 2025)

Historic Equity Average for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $29.8 million.

  • Immucell's Equity Average rose 1965.45% to $29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year increase of 1965.45%. This contributed to the annual value of $26.3 million for FY2024, which is 516.83% down from last year.
  • According to the latest figures from Q3 2025, Immucell's Equity Average is $29.8 million, which was up 1965.45% from $29.4 million recorded in Q2 2025.
  • In the past 5 years, Immucell's Equity Average registered a high of $32.9 million during Q1 2022, and its lowest value of $24.0 million during Q2 2024.
  • Its 5-year average for Equity Average is $28.9 million, with a median of $29.3 million in 2023.
  • Its Equity Average has fluctuated over the past 5 years, first crashed by 1820.96% in 2023, then soared by 2239.36% in 2025.
  • Quarter analysis of 5 years shows Immucell's Equity Average stood at $32.5 million in 2021, then fell by 4.11% to $31.2 million in 2022, then fell by 18.21% to $25.5 million in 2023, then rose by 5.73% to $27.0 million in 2024, then grew by 10.64% to $29.8 million in 2025.
  • Its last three reported values are $29.8 million in Q3 2025, $29.4 million for Q2 2025, and $28.3 million during Q1 2025.